Develops antibody therapeutics by leveraging deep learning and adaptive immunity to identify and replicate antibodies from resilient individuals, such as long-term cancer survivors. This approach targets hard-to-treat diseases, providing a potential solution for conditions like Parkinson’s disease.
Funding
$83M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MJFounders
Product
Problem
Many diseases, such as cancer and Parkinson's, are difficult to treat effectively with existing therapies. Identifying and developing new therapeutic antibodies for these conditions is a complex and time-consuming process. Traditional drug discovery methods often struggle to replicate the natural human immune response to disease.
Solution
Alchemab Therapeutics leverages the adaptive immune system of resilient individuals, such as long-term cancer survivors, to discover and develop novel antibody therapeutics. By studying the antibodies present in these individuals, Alchemab identifies naturally occurring antibodies that have demonstrated efficacy in combating disease. The company then uses deep learning and other advanced technologies to characterize and replicate these antibodies, creating potential treatments for hard-to-treat diseases. This approach aims to harness the power of the human immune system to develop more effective and targeted therapies.
Target Audience
The primary target audience includes patients suffering from hard-to-treat diseases, as well as pharmaceutical companies seeking novel antibody therapeutics for their pipelines.
Features
- Identification of protective antibodies from resilient individuals with exceptional resistance to disease.
- Deep learning-based analysis of antibody repertoires to identify promising therapeutic candidates.
- Replication and optimization of naturally occurring antibodies for therapeutic development.
- Focus on developing treatments for diseases with limited or ineffective existing therapies.